AOD-9604: What It Is and How It Works
Part of the Compound Research topic cluster · editorial policy
A plain-English guide to AOD-9604, the modified HGH fragment studied for lipid-metabolism pathways. What the published evidence shows and where the claims outrun the data.
AOD-9604 is a modified fragment of human growth hormone - a small piece of the molecule, not the whole thing. It was developed to study whether a fragment could affect lipid (fat) metabolism without the broad effects of full growth hormone. This guide covers what the research actually shows.
What researchers are exploring
The core question behind AOD-9604 research is simple: can a fragment of growth hormone influence how cells process fat? The published work looks at three levels: cells, fat tissue, and whole animals.
- How AOD-9604 affects fat metabolism in cultured liver cells
- Whether it changes lipolysis - fat breakdown - in human fat cells
- Reported effects on body weight in mice
How it may work
The idea is that the fragment interacts with the same signalling systems growth hormone uses to regulate fat metabolism, but without triggering the full receptor activity of the whole hormone. The papers describe effects on lipolysis in fat cells and lipid processing in liver cells.[1], [2]
What the evidence says
Cell-level work
Studies in cultured human fat cells and liver cells reported that AOD-9604 changes lipid-processing activity in those specific models.[1], [2] These are controlled lab observations about cell chemistry.
Animal work
A mouse study from the same group reported reduced body weight gain with AOD-9604 treatment.[3] One study, one group, one rodent model.
What is missing
There is no modern, large, independent human trial. Most of the published work comes from the early 2000s and a small group of researchers. Online claims about fat loss go far beyond the source data.
What we still don't know
- Whether the cell-level lipid findings translate to whole-body outcomes
- How the fragment behaves over weeks or months in an organism
- Independent replication of the mouse weight finding
- Any validated dose-response relationship
How to interpret the current evidence
AOD-9604 is a legitimate research peptide with a small, dated, mostly single-group evidence base. The cell and mouse findings are citable. The human fat-loss claims are not supported by the literature. Plan experiments around what the papers actually show.
Compliance reminder
AOD-9604 is supplied for research and educational purposes only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and must not be consumed by humans or animals.
Researching metabolic pathways? View AOD-9604. For related research, see the incretin receptor biology review and triple agonism and Retatrutide.
Primary sources
Links lead to the original paper, DOI record, or open-access full text where available.
- Heffernan M, et al. The effect of the growth hormone fragment AOD-9604 on lipid metabolism in human hepatocytes. Journal of Endocrinology. 2001;171(3):491-497.
- Ng FM, et al. The effects of the GH fragment AOD-9604 on lipolysis in human fat cells. Journal of Endocrinology. 2001;171(3):499-506.
- Heffernan M, et al. Growth hormone fragment AOD-9604 reduces body weight gain in mice. Journal of Endocrinology. 2000;167(3):495-504.
This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.